NEW YORK, June 16, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell...
Neuroethicist and psychiatrist are recognized for innovation and transformative interdisciplinary work to advance neuroscience's benefits to society NEW YORK, June...
Highlight brain imaging analysis solutions, including 'Neurophet AQUA AD', which monitors side effects from Alzheimer's disease treatmentsTo accelerate partnering efforts...
SCOTTSDALE, Ariz., June 12, 2025 /PRNewswire/ -- Amendola, an award-winning, insights-driven public relations and marketing firm that is part of...
VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”),...
VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”),...
VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”),...
Ra’anana, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a biotechnology company developing...
Ra’anana, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a biotechnology company developing...
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people...
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people...
SARASOTA, Fla. and HUNTSVILLE, Ala., June 11, 2025 /PRNewswire/ -- World Precision Instruments (WPI), a global leader in transepithelial electrical resistance...
CHICAGO, June 11, 2025 /PRNewswire/ -- The Global Digital Health Market size is projected to be valued at USD 347.35 billion...
HUNTSVILLE, Texas, June 11, 2025 /PRNewswire/ -- Zeto, Inc. is proud to announce the success of a new onsite EEG...
Vanessa Tolosa joins as Senior Vice President of Research and Development; Vivek Pinto as Director of Medical AffairsNEW YORK, June...
In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed: Twice the Reported 2.25...
Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on...
Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on...
RAD101 in U.S. Phase 2 clinical trial to distinguish between recurrent disease and treatment effect of brain metastases originating from...
Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trialBURLINGTON,...